Literature DB >> 20701838

Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study.

Marilyn F Dille1, Dawn Konrad-Martin, Frederick Gallun, Wendy J Helt, Jane S Gordon, Kelly M Reavis, Gene W Bratt, Stephen A Fausti.   

Abstract

BACKGROUND AND
PURPOSE: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset? DATA COLLECTION AND ANALYSIS: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and chi(2) statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug.
RESULTS: Baseline tinnitus rates were high (nearly 47%) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment.
CONCLUSIONS: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed. American Academy of Audiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20701838      PMCID: PMC5590654          DOI: 10.3766/jaaa.21.6.6

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  22 in total

Review 1.  Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus.

Authors:  Leonard P Rybak
Journal:  Int Tinnitus J       Date:  2005

2.  An individualized, sensitive frequency range for early detection of ototoxicity.

Authors:  S A Fausti; J A Henry; W J Helt; D S Phillips; R H Frey; D Noffsinger; V D Larson; C G Fowler
Journal:  Ear Hear       Date:  1999-12       Impact factor: 3.570

3.  Early detection of ototoxicity using 1/6th-octave steps.

Authors:  Stephen A Fausti; Wendy J Helt; David S Phillips; Jane S Gordon; Gene W Bratt; Karen M Sugiura; Douglas Noffsinger
Journal:  J Am Acad Audiol       Date:  2003-10       Impact factor: 1.664

4.  Rate of false-positive results for threshold shifts during initial treatment with aminoglycosides.

Authors:  Nicolas Schmuziger; Nicolas Gürtler; Manuel Jungi; Alois Gratwohl; Rudolf Probst
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2004       Impact factor: 1.538

5.  Extended-interval aminoglycoside administration for children: a meta-analysis.

Authors:  Despina G Contopoulos-Ioannidis; Nikos D Giotis; Dimitra V Baliatsa; John P A Ioannidis
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

6.  The burdens of age-related and occupational noise-induced hearing loss in the United States.

Authors:  Robert A Dobie
Journal:  Ear Hear       Date:  2008-08       Impact factor: 3.570

7.  An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity.

Authors:  Nancy E Vaughan; Stephen A Fausti; Stephen Chelius; David Phillips; Wendy Helt; James A Henry
Journal:  J Rehabil Res Dev       Date:  2002 Sep-Oct

8.  Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

Authors:  Sophie D Fosså; Ronald de Wit; J Trevor Roberts; Peter M Wilkinson; Pieter H M de Mulder; Graham M Mead; Pat Cook; Linda de Prijck; Sally Stenning; Neil K Aaronson; Andrew Bottomley; Laurence Collette
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.

Authors:  J Kopelman; A S Budnick; R B Sessions; M B Kramer; G Y Wong
Journal:  Laryngoscope       Date:  1988-08       Impact factor: 3.325

10.  Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Authors:  C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more
  16 in total

Review 1.  Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?

Authors:  Sofia Waissbluth
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-05-01       Impact factor: 2.503

Review 2.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

3.  A Protocol for Decellularizing Mouse Cochleae for Inner Ear Tissue Engineering.

Authors:  Christopher A Neal; Jennifer G Nelson-Brantley; Michael S Detamore; Hinrich Staecker; Adam J Mellott
Journal:  J Vis Exp       Date:  2018-01-01       Impact factor: 1.355

4.  Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring.

Authors:  Dawn Konrad-Martin; Kristin Knight; Garnett P McMillan; Laura E Dreisbach; Elsa Nelson; Marilyn Dille
Journal:  Ear Hear       Date:  2020 Mar/Apr       Impact factor: 3.570

5.  Development and validation of a cisplatin dose-ototoxicity model.

Authors:  Marilyn F Dille; Debra Wilmington; Garnett P McMillan; Wendy Helt; Stephen A Fausti; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2012 Jul-Aug       Impact factor: 1.664

6.  A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.

Authors:  Marilyn F Dille; Garnett P McMillan; Wendy J Helt; Dawn Konrad-Martin; Peter Jacobs
Journal:  J Am Acad Audiol       Date:  2015-10       Impact factor: 1.664

Review 7.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.

Authors:  Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille
Journal:  Int J Audiol       Date:  2017-11-20       Impact factor: 2.117

8.  ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.

Authors:  Marilyn F Dille; Roger M Ellingson; Garnett P McMillan; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2013-10       Impact factor: 1.664

9.  The distressed brain: a group blind source separation analysis on tinnitus.

Authors:  Dirk De Ridder; Sven Vanneste; Marco Congedo
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

10.  Audiometric Predictors of Bothersome Tinnitus in a Large Clinical Cohort of Adults With Sensorineural Hearing Loss.

Authors:  Rebecca M Lewis; Kelly N Jahn; Aravindakshan Parthasarathy; William B Goedicke; Daniel B Polley
Journal:  Otol Neurotol       Date:  2020-04       Impact factor: 2.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.